Enveric Biosciences (ENVB) Interest Coverage Ratio (2013 - 2025)
Enveric Biosciences (ENVB) posted Interest Coverage Ratio of 66.7 for Q4 2025, up 34.06% sequentially from 101.15 in Q4 2024, and up 34.06% YoY from 49.75 in Q4 2024.
Enveric Biosciences (ENVB) Interest Coverage Ratio (2013 - 2025) Analysis & Trends
Enveric Biosciences has reported Interest Coverage Ratio for 13 years, with the latest figure at 66.7 in Q4 2025.
- Quarterly Interest Coverage Ratio rose 34.06% year-over-year to 66.7 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 266.77 (up 13.1% YoY) and the FY2025 annual result came in at 266.77, down 426.2% from the prior year.
- Interest Coverage Ratio rose to 66.7 in Q4 2025 per ENVB's latest filing, from 101.15 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 0.19 in Q4 2023 and troughed at 441879.82 in Q1 2023.
- A 5-year average of 47450.43 and a median of 630.07 in 2022 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2022 and 2023: Interest Coverage Ratio slumped 381361.79% in 2022, then soared 100.0% in 2023.
- Over 5 years, Interest Coverage Ratio stood at 9947.03 in 2021, then plunged by 812.66% to 90782.61 in 2022, then jumped by 100.0% to 0.19 in 2023, then sank by 54363.15% to 101.15 in 2024, then surged by 34.06% to 66.7 in 2025.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 66.7, 101.15, and 0.19 for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -66.70 |
| Dec 31, 2024 | -101.15 |
| Dec 31, 2023 | -0.19 |
| Mar 31, 2023 | -441,879.82 |
| Dec 31, 2022 | -90,782.61 |
| Sep 30, 2022 | -18,366.39 |
| Jun 30, 2022 | -7,046.05 |
| Mar 31, 2022 | -1,158.98 |
| Dec 31, 2021 | -9,947.03 |
| Sep 30, 2021 | -4.81 |
| Jun 30, 2021 | -40.80 |
| Mar 31, 2021 | -10.63 |
| Dec 31, 2020 | -61.70 |
| Sep 30, 2020 | -0.55 |
| Jun 30, 2020 | -0.84 |
| Mar 31, 2020 | -3.20 |
| Dec 31, 2019 | -4.35 |
| Sep 30, 2019 | -6.15 |
| Jun 30, 2019 | -4.66 |
| Mar 31, 2019 | -9.06 |